http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4065633-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C53-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-5407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C51-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C53-19
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C53-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C401-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C53-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-935
filingDate 1976-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1977-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14a6244a927b23b670b5f569a75a405f
publicationDate 1977-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-4065633-A
titleOfInvention 2,2-Difluoro-13,14-dihydro-PGA1 analogs
abstract 2,2-Difluoro prostaglandin E, F.sub.α, F.sub.β, A, and B analogs are disclosed with intermediates and with processes for making them. These compounds differ from the prostaglandins in that they have two fluoro atoms at the C-2 position in place of the two hydrogen atoms at C-2 in the prostaglandins. These compounds are useful for a variety of pharmacological purposes, including antiulcer, inhibition of platelet aggregation, increase in nasal patency, labor induction at term, and wound healing.
priorityDate 1975-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3919286-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3962293-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457280508
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457192620
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155

Total number of triples: 43.